Liabilities / Assets
71st percentile
Higher debt load relative to assets than 71% of similar nonprofits.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.14x
Liabilities / Revenue
71st percentile
Higher debt load relative to revenue than 71% of similar nonprofits.
Net Margin
13th percentile
Higher net margin than 13% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
9th percentile
Faster asset growth than 9% of similar nonprofits.
Revenue Growth
89th percentile
Faster revenue growth than 89% of similar nonprofits.
Balance Sheet
Assets
Down$712,390
Down $194,080 (-21%) from 2022
Net Assets
Down$610,490
Down $194,080 (-24%) from 2022
Liabilities
Flat$101,900
Flat from 2022
Revenue And Expenses
Revenue
Up$772,336
Up $353,716 (+84%) from 2022
Expenses
Up$966,416
Up $658,079 (+213%) from 2022
Net Income
Down-$194,080
Down $304,363 (-276%) from 2022
Historical Trend
Filing Detail Status
This 2023 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2023 to Dec 31, 2023
Mission and Program Overview
Mission
Seeking a cure or preventative treatment for NF2 by vigorously supporting and advancing existing and next generation biomedical technologies such as gene transfer therapy and immunontherapy
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2023 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $712,390
- Liabilities
- $101,900
- Net assets
- $610,490
- Revenue
- $772,336
- Expenses
- $966,416
- Net income
- -$194,080